Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report.
BMC Pulm Med
; 18(1): 193, 2018 Dec 12.
Article
in En
| MEDLINE
| ID: mdl-30541518
ABSTRACT
BACKGROUND:
Pulmonary carcinosarcoma (PCS) is a rare primary lung malignancy and has a poor prognosis among lung tumor histological subtypes. However, an appropriate treatment strategy has not been developed for unresectable PCS. CASE PRESENTATION A 65-year-old man who was diagnosed with PCS was treated by surgical removal of the primary lung lesion, followed by six cycles of adjuvant chemotherapy with cisplatin plus irinotecan. Following the chemotherapy, he experienced a relapse with brain metastasis, which induced the rapid onset of left leg paralysis. Radical surgical resection and stereotactic radiosurgery to the resection cavity were performed. However, meningeal dissemination and new lung metastases occurred after a year and half. To control these multiple metastatic lesions, the patient was treated with the multiple kinase inhibitor pazopanib. No change was observed in the meningeal dissemination, while the metastatic lung lesions were prominently reduced in size following treatment with pazopanib. Consequently, the patient showed a partial response to pazopanib treatment, although the dose of pazopanib was reduced by half as a result of thrombocytopenia.CONCLUSION:
This is the first report of metastatic PCS showing an evident therapeutic response to tumor-targeted therapy. We suggest that pazopanib may be a therapeutic option for patients with metastatic PCS.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pneumonectomy
/
Pyrimidines
/
Sulfonamides
/
Thrombocytopenia
/
Brain Neoplasms
/
Carcinosarcoma
/
Lung Neoplasms
/
Meningeal Neoplasms
Type of study:
Prognostic_studies
Limits:
Aged
/
Humans
/
Male
Language:
En
Journal:
BMC Pulm Med
Year:
2018
Type:
Article
Affiliation country:
Japan